46 results about "Inhibitor protein" patented technology

The invention provides a wheat cell, part, tissue culture or whole plant comprising at least one disrupted KRP gene of the present invention. The present invention also provides methods of increasing weight, size, and/or number of one or more organs, and/or yield of a wheat plant by utilizing the disrupted KRP genes of the present invention. Furthermore, methods of breeding wheat plants to produce new wheat plants having increased weight, size, and/or number of one or more organs, and/or yield are provided. The present invention provides isolated Kinase Inhibitor Protein (KIP) Related Protein (KRP) polynucleotide sequences and isolated KRP polypeptide sequences and methods of their use.

The invention relates to Inter-alpha inhibitor proteins (IαIp). The invention further relates to processes for purification of IαIp compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.

The present invention relates to an inner-alpha inhibitor protein (I alpha Ip). The invention also relates to a method for purifying the I alpha Ip composition and the usage for treating the human diseases such as pyaemia, septicemic shock, atrophic arthritis, cancer and infectious disease.

The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.

The invention relates to the technical field of medical treatment. The tea double-chlorine carboxamide and tea double-bromine carboxamide are newly synthesized compounds which can inhibit growths and invasions of cancer cells such as lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, prostate cancer, pancreatic cancer, cervical cancer, lymphoma, leukemia, and melanoma, and can obviously inhibit the tumor growth and metastasis in the body, and the inhibition effect of the compound is better than that of an anticancer medicament; the mechanism of action involves a receptor which is closely related to down-regulation and inhibition of the growth, invasion and metastasis of a tumor, signal transduction and regulation protein and kinase levels and a binding of a nuclear factor and DNA (Deoxyribonucleic Acid), and up-regulation of factors such as tumor suppressor proteins and cell cycle inhibitor proteins simultaneously; double tea chlorine carboxamide and double tea chlorine carboxamide can directly inhibit activities of histone deacetylase and histone methyltransferase EZH2(Enhancer Of Zeste Homolog 2) and the binding of the inflammatory factor NF-kB and DNA, and the activities of tea double-chlorine carboxamide and tea double-bromine carboxamide are better than that of the clinical anti-cancer medicament. The invention provides new applications of tea double-chlorine carboxamide and tea double-bromine carboxamide and intermediate compounds in preventing and treating the diseases such as cancers, inflammation, cardiovascular and immune deficiencies.

The invention provides metastatic tumor deletion protein small-molecule cyclopeptide, derivatives or salts thereof, a preparation method for the metastatic tumor deletion protein small-molecule cyclopeptide, the derivatives or salts thereof and an application of the metastatic tumor deletion protein small-molecule cyclopeptide, the derivatives or salts thereof in preparation of antitumor medicaments. The metastatic tumor deletion protein small-molecule cyclopeptide is low in molecular weight, high in stability and very low in toxicity and can enter cells through cell membranes to inhibit endocytosis of tumor cells and interfere morphologic change of the cell membranes and conduction of relevant antitumor signals by inhibiting dimerization of Mtss1 protein, so that cell proliferation and growth caused by tumor stimulating factors such as epidermal growth factors EGF, platelet derived growth factor PDGF or sonic hedgehog (shh) factors are weakened, wherein the in-vitro inhibition activity of nanomole-scale inhibitor-protein can remarkably inhibit the endocytosis of the cells after the inhibitor-protein is directly added into cell culture fluid without being transfected or packaged by lipidosome.

The invention provides a plant cell, part, tissue culture or whole plant comprising at least one disrupted KRP gene of the present invention. The present invention also provides methods of increasing weight, size, and/or number of one or more organs, and/or yield of a plant by utilizing the disrupted KRP genes of the present invention. Furthermore, methods of breeding plants to produce new plants having increased weight, size, and/or number of one or more organs, and/or yield are provided. The present invention provides isolated Kinase Inhibitor Protein (KIP) Related Protein (KRP) polynucleotide sequences and isolated KRP polypeptide sequences and methods of their use. Exemplary plants include wheat, rice and soybean.

The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins.

The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (1-1). In particular, the 1-1 mutant forms comprise altered phosphorylation sites of PKC-α. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and heart failure, which employ the novel nucleic acids and polypeptides. Vectors comprising the novel nucleic acids, Antibodies to the novel proteins, and diagnostic and screening methods associated therewith, are also provided.

A phospholipase A₂ inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases. Also, phospholipase A₂ (PLA₂) inhibitory polypeptides designated P-0029, P-0009, and P-0006, the sequences of which are given as SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, are disclosed. Those polypeptides, and their synthetic chemical analogues and polypeptide variants that inhibit PLA₂ activity and alleviate inflammation, may also be used in the diagnosis, study, prevention, and treatment of PLA₂-related human inflammatory diseases.

The invention provides a new telomerase inhibition of active protein- MCRS2 protein, polynucleotides of coded MCRS2 protein and the method produced by recombination technology. The invention also discloses the application of MCRS2 protein and its coded sequence that the MCRS2 protein has the capacity of making the chromosome telomeric of liver cancer cells short and inhibiting telomerase activity.

The present invention concerns a nucleic acid molecule capable of expressing, in at least one plant tissue, a chimeric protein comprising a polygalacturonase (PG) of fungal, bacterial or insect origin and a plant polygalacturonase inhibitor protein (PGIP) plant capable of inhibiting said PG. The present invention also relates to transgenic plants that express said chimeric protein.

The invention discloses nearly 123 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, phosphatase/phospholipases, G proteins/GTPase activating proteins/guanine nucleotide exchange factors, cellular metabolism enzymes, DNA binding proteins, cytoskeletal proteins, cell cycle regulation proteins, proteases, RNA binding proteins, transcription proteins, translation initiation complex proteins, transferases, ubiquitin conjugating system proteins, vesicle proteins, actin binding proteins, apoptosis proteins, chemokine proteins, enzyme proteins extra cellular matrix proteins, helicases, hydrolases, immunoglobin superfamily proteins, inhibitor proteins, isomerases, ligases, lipid binding proteins, methyltransferases, motor proteins, receptor proteins, and chaperone proteins.

Described herein are methods for quantifying lAIP levels in a sample (e.g., from a subject) using lAIP ligand-based assays. Also disclosed are methods for measuring lAIP-IAIP ligand complexes, and methods of evaluating, monitoring, and treating subjects using the aforementioned lAIP quantification methods.

The present invention relates to novel protease inhibitor proteins that have been identified in ticks. These proteins may be used as components of vaccines, as inhibitors of mast cell tryptase, in detection of mast cells and in the isolation and purification of mast cell tryptase. The invention also relates to the control of diseases and injury caused by parasites in animals and humans and to the use of the proteins of the invention in the treatment of certain diseases and allergies.

The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-[alpha] inhibitor proteins (l[alpha]lps), including, e.g., inter-alpha inhibitor (l[alpha]l) and/or pre-alpha inhibitor (P[alpha]l).